FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC-Reference-Cited by-同舟云学术

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Published:2018-11 Issue:11 Volume:13 Page:1733-1742
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Spigel David R.,Chaft Jamie E.,Gettinger Scott,Chao Bo H.,Dirix Luc,Schmid Peter,Chow Laura Q.M.,Hicks Rodney J.,Leon Larry,Fredrickson Jill,Kowanetz Marcin,Sandler Alan,Funke Roel,Rizvi Naiyer A.

Funder

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non–small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group;Fossella;J Clin Oncol,2000

2. Prospective randomized trial of docetaxel versus best supportive care in patients with non–small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

3. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer;Brahmer;N Engl J Med,2015

4. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015

5. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting resistance and pseudoprogression: are minimalistic immunoediting mathematical models capable of forecasting checkpoint inhibitor treatment outcomes in lung cancer?;Mathematical Biosciences;2024-10

2. The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases;CLIN LUNG CANCER;2024

3. The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases;Clinical Lung Cancer;2024-09

4. Comparative Efficacy and Safety of Immunotherapy on Non–Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Network Meta‐Analysis;The Clinical Respiratory Journal;2024-08

5. Predict progression free survival and overall survival using objective response rate for anti—PD1/PDL1 therapy development;BMC Cancer;2024-07-29